The goal of this study was to perform an extensive temporal characterization of the early pathologic processes in the streptozotocin (STZ)–induced diabetic retinopathy (DR) mouse model, beyond the vascular phenotype, and to investigate the potential of clinically relevant compounds in attenuating these processes.